Opthea (ASX:OPT) EV-to-EBIT : -0.45 (As of May. 31, 2024)

View and export this data going back to 1991. Start your Free Trial

What is Opthea EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Opthea's Enterprise Value is A$100.72 Mil. Opthea's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-223.93 Mil. Therefore, Opthea's EV-to-EBIT for today is -0.45.

The historical rank and industry rank for Opthea's EV-to-EBIT or its related term are showing as below:

ASX:OPT' s EV-to-EBIT Range Over the Past 10 Years
Min: -22.37 Med: -7.19 Max: -0.45
Current: -0.45

During the past 13 years, the highest EV-to-EBIT of Opthea was -0.45. The lowest was -22.37. And the median was -7.19.

ASX:OPT's EV-to-EBIT is ranked worse than
100% of 427 companies
in the Biotechnology industry
Industry Median: 9.72 vs ASX:OPT: -0.45

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Opthea's Enterprise Value for the quarter that ended in Dec. 2023 was A$143.33 Mil. Opthea's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-223.93 Mil. Opthea's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -156.23%.

Opthea EV-to-EBIT Historical Data

The historical data trend for Opthea's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea EV-to-EBIT Chart

Opthea Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EV-to-EBIT

Get a 7-Day Free Trial

-3.85

-23.23

-4.78

-2.30

-0.62

Opthea Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-	-2.30	-	-0.62	-

Competitive Comparison of Opthea's EV-to-EBIT

For the Biotechnology subindustry, Opthea's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opthea's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opthea's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Opthea's EV-to-EBIT falls into.

Opthea EV-to-EBIT Calculation

Opthea's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	100.716	/	-223.932
	=	-0.45

Opthea's current Enterprise Value is A$100.72 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Opthea's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-223.93 Mil.

Opthea (ASX:OPT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Opthea's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-223.932	/	143.33299
	=	-156.23 %

Opthea's Enterprise Value for the quarter that ended in Dec. 2023 was A$143.33 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Opthea's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-223.93 Mil.

Opthea EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Opthea's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Opthea (ASX:OPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (ASX:OPT) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

OPT:USA UKJ:Germany

Address

650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141

Website

https://www.opthea.com

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.